中文版 English
News > YHLO News
Excellent Performance of SARS-CoV-2 IgM/IgG Kits in Thailand
“A total of 113,702 confirmed cases of COVID-19 have been reported globally as of 10:00 CET Tuesday, an increase of 4,125 infections from the previous day, among which 4,105 new infections are outside China.” ——from Xinhua Net on 2020-3-11

At the time of the large-scale outbreak of the novel coronavirus (COVID-19, SARS-CoV-2), fast and fully-automated diagnostic tools are in urgent need for clinical doctors to well support a large number of screening in hospitals. As one of the first companies developed CLIA assays for novel coronavirus, YHLO’s SARS-CoV-2 IgM/IgG kits have been sent to almost 400 Chinese hospitals and labs, especially Wuhan major hospitals, to help diagnose and screen COVID-19. 

Alongside the spread of the novel coronavirus, an increasing number of the infections have been confirmed worldwide. At this critical period, YHLO’s SARS-CoV-2 IgM/IgG kits can also bring a powerful support for hospitals around the world to fight the outbreak.

In Thailand, Bamrasnaradura Institute of Infectious Diseases, the core hospital for infectious diseases, is pointed by local government to be the first and the only hospital in the country which can accept COVID-19 cases. The diagnostic device they are using is YHLO's iFlash 1800, together with its SARS-CoV-2 IgM/IgG kits.


“Prime Minister Prayut Chan-o-cha made a surprise visit to Bamrasnaradura Institute of Infectious Diseases this evening (Tuesday), to offer moral support to medical personnel and patients infected with COVID-19. Accompanied by Public Health Minister Anutin Charnvirakul, Public Health Permanent Secretary Dr. Sukhum Kanchanapimai and senior health officials, the Prime Minister visited the ARI clinic, which screens patients suffering from respiratory diseases, and was briefed about the activities of the institute, which serves as the centre for the testing and treatment of coronavirus infection.” —— from Thai PBS World on 2020-3-10

Bamrasnaradura Institute analyzed the test results of SARS-CoV-2 IgM and SARS-CoV-2 IgG from iFlash 1800 and found that these kits demonstrated excellent performance, the sensitivity and specificity conformed to the results. Antibody testing is a valuable supplementary tool for RT-PCR, and it is especially useful for patients with negative RT-PCR results.

YHLO have obtained the CE certificates of SARS-CoV-2 IgM and SARS-CoV-2 IgG. We are ready to offer the best solutions of novel coronavirus to help win the battle.

CopyRight@2019 Shenzhen YHLO Biotech Co., Ltd. rights reserved
Headquarter: Building 1, YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict, Longgang District, 518116 Shenzhen, P.R.China
Int'l Business Office: Rm.501, Building A1, Kexing Science Park, No.15 Keyuan Road, Nanshan District, 518057 Shenzhen, P.R.China
Tel: +86 755 26601910   /   Fax: +86 755 26473319   /   Email: marketing@szyhlo.com

About YHLONewsProductsServicesJoin UsInvestor RelationsContact Us